Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
03/19/2024 03:10 AM
By REUTERS
03/19/2024 02:42 AM
By REUTERS
03/19/2024 01:15 AM
By REUTERS
03/18/2024 11:37 PM
By REUTERS
03/18/2024 10:18 PM
By REUTERS
03/18/2024 08:40 PM
By REUTERS
03/18/2024 07:55 PM
By REUTERS
03/18/2024 02:45 PM
By REUTERS
03/18/2024 01:36 PM